# Desidustat in the Management of COVID-19 Patients

> **NCT04463602** · PHASE2 · COMPLETED · sponsor: **Zydus Lifesciences Limited** · enrollment: 24 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Desidustat
- **OTHER:** Standard of Care

## Key facts

- **NCT ID:** NCT04463602
- **Lead sponsor:** Zydus Lifesciences Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-25
- **Primary completion:** 2021-01-25
- **Final completion:** 2021-03-31
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2021-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04463602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04463602, "Desidustat in the Management of COVID-19 Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04463602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*